ES2149163T3 - Nuevos analogos trans-ciclopentanilpurina utiles como inmunosupresores. - Google Patents

Nuevos analogos trans-ciclopentanilpurina utiles como inmunosupresores.

Info

Publication number
ES2149163T3
ES2149163T3 ES92120653T ES92120653T ES2149163T3 ES 2149163 T3 ES2149163 T3 ES 2149163T3 ES 92120653 T ES92120653 T ES 92120653T ES 92120653 T ES92120653 T ES 92120653T ES 2149163 T3 ES2149163 T3 ES 2149163T3
Authority
ES
Spain
Prior art keywords
immunosuppressants
cyclopentanylpurine
analogs useful
trans
new trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92120653T
Other languages
English (en)
Inventor
David R Borcherding
Ronald E Esser
Carl K Edwards Iii
Douglas L Cole Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2149163T3 publication Critical patent/ES2149163T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL INVENTO SE REFIERE A ANALOGOS DE PURINA DE TRANS CICLOPENTANILO DE LA FORMULA (1) DONDE EL SUSTITUYENTE EN LA POSICION 3 EN EL ANILLO CICLOPENTANILO ESTA EN LA CONFIGURACION TRANS EN RELACION CON EL SUSTITUYENTE BICICLICO, Y3, Y5, Y7, Y8 E Y9 SON CADA UNO INDEPENDIENTEMENTE NITROGENO O UN GRUPO CH, R ES UN HIDROGENO, O UN ACILO ALQUILO C1 UNA SAL FARMACEUTICAMENTE ACEPTABLE CONSIGUIENTE, Y SU USO COMO INMUNOSUPRESORES.
ES92120653T 1991-12-06 1992-12-03 Nuevos analogos trans-ciclopentanilpurina utiles como inmunosupresores. Expired - Lifetime ES2149163T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80415391A 1991-12-06 1991-12-06
US96560192A 1992-11-02 1992-11-02

Publications (1)

Publication Number Publication Date
ES2149163T3 true ES2149163T3 (es) 2000-11-01

Family

ID=27122672

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92120653T Expired - Lifetime ES2149163T3 (es) 1991-12-06 1992-12-03 Nuevos analogos trans-ciclopentanilpurina utiles como inmunosupresores.

Country Status (17)

Country Link
EP (1) EP0545413B1 (es)
JP (1) JP3264289B2 (es)
KR (1) KR100251996B1 (es)
AT (1) ATE194618T1 (es)
AU (1) AU658698B2 (es)
CA (1) CA2084222C (es)
DE (1) DE69231242T2 (es)
DK (1) DK0545413T3 (es)
ES (1) ES2149163T3 (es)
FI (1) FI109026B (es)
GR (1) GR3034586T3 (es)
HU (2) HU217077B (es)
IL (1) IL103962A (es)
MX (1) MX9206963A (es)
NO (1) NO305207B1 (es)
NZ (1) NZ245342A (es)
PT (1) PT545413E (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0705263T3 (da) 1993-06-21 1997-05-05 Merrell Pharma Inc Carbocycliske nukleoside midler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner
ES2232871T3 (es) * 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038479A (en) * 1969-11-17 1977-07-26 Burroughs Wellcome Co. Amino purine derivatives
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
CA2001715C (en) * 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
EP0465297B1 (en) * 1990-07-04 1996-01-31 Merrell Dow Pharmaceuticals Inc. 9-Purinyl phosphonic acid derivatives
CA2051012C (en) * 1990-09-14 2002-04-02 David R. Borcherding Carbocyclic adenosine analogs useful as immunosupressants

Also Published As

Publication number Publication date
HU9203858D0 (en) 1993-03-29
EP0545413A1 (en) 1993-06-09
NO924691L (no) 1993-06-07
PT545413E (pt) 2000-10-31
AU2975292A (en) 1993-06-10
IL103962A0 (en) 1993-05-13
FI925520A0 (fi) 1992-12-04
JPH0656835A (ja) 1994-03-01
KR100251996B1 (ko) 2000-09-01
HUT62896A (en) 1993-06-28
NZ245342A (en) 1995-10-26
FI109026B (fi) 2002-05-15
FI925520L (fi) 1993-06-07
GR3034586T3 (en) 2001-01-31
CA2084222C (en) 2004-04-06
MX9206963A (es) 1993-06-01
DE69231242D1 (de) 2000-08-17
DK0545413T3 (da) 2000-10-09
IL103962A (en) 1997-01-10
HU217077B (hu) 1999-11-29
JP3264289B2 (ja) 2002-03-11
ATE194618T1 (de) 2000-07-15
DE69231242T2 (de) 2000-12-21
NO924691D0 (no) 1992-12-04
NO305207B1 (no) 1999-04-19
CA2084222A1 (en) 1993-06-07
EP0545413B1 (en) 2000-07-12
AU658698B2 (en) 1995-04-27

Similar Documents

Publication Publication Date Title
FI931493A7 (fi) Pesuainekoostumuksia, jotka sisältävät oleellisesti puhdasta EG-III-se llulaasia
ES2118835T3 (es) 2-etil-1h-imidazo(4,5-c)quinolin-4-aminas antiviricas.
FI934465A7 (fi) Tiivis pesuainekoostumus, joka sisältää polyvinyylipyrrolidonia
ATE110382T1 (de) Oxetanocin.
ES2149163T3 (es) Nuevos analogos trans-ciclopentanilpurina utiles como inmunosupresores.
ES8706163A1 (es) Procedimiento para la fabricacion de nuevos derivados nu- cleosidos
FI932997A0 (fi) Antivirala foereningar
ITRE910029A0 (it) Gruppo stallonatore ad elevata flessibilita' di impiego
ES2162406T3 (es) Nuevos compuestos espirociclicos.
IS4436A (is) Núkleósíðhliðstæður sem vinna gegn veirum og innihalda benzimidazole basa með skiptihópum, sem er tengdur við kolefnishring
EP0521463A3 (en) Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
IT1251202B (it) 6-amminochinoloni, sintesi ed impiego come antibatterici
DK0472181T3 (da) 5-Amino-substituerede adenosinanaloge som immunsuppresiva
IT211213Z2 (it) Gruppo di giunzione per la composizione di strutture tubolari di supporto di gruppi illuminta.
GB9111967D0 (en) 2,5'-nucleotide analogs as antiviral agents
DK0717731T3 (da) Antivirale difluorstatonanaloge
ES8708222A1 (es) Un procedimiento para la preparacion de derivados condensados dibenzo triciclos nuevos.
陈焕艮 Reduced groups of abelian group rings
MY102247A (en) Phosphorylated acylglycosides, their preparation and use
ZA916350B (en) 5'-vinylhalo-aristeromycin/adenosine analogs as immunosuppressants
ES2063561T3 (es) 6-tiono-5,6-dihidro-dibenz(b,e)azepin-11-on-11-oximas y su uso como agentes retrovirales.
IT8704911V0 (it) Flacone costituito come dalla parziale compenetrazione di due corpi parallelepipedi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 545413

Country of ref document: ES